ImmuneOnco Biopharmaceuticals (Shanghai) Inc
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
ImmuneOnco is a publicly traded, clinical-stage biotechnology company focused on discovering and developing therapies for cancer, autoimmune, cardiovascular, and metabolic diseases. Our wholly owned pipeline ranges from preclinical to Phase III programs, all originating from our internal research platform. We actively seek strategic collaborations and out-licensing partnerships to advance our innovative therapies globally.
Company HQ City:
Shanghai
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2015
Lead Product in Development:
IMM01, IMM0306, IMM2510
CEO
Wenzhi Tian
Development Phase of Lead Product
Phase III
Exchange
HKEX
Ticker
1541
When you expect your next catalyst update?
Dec. 2026
What is your next catalyst (value inflection) update?
Phase III data for IMM01,IMM0306 in oncology, Phase II datafor IMM0306 in SLE
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}